What You Should Know:
– Dedalus Group, an anatomic pathology information systems provider in Europe, and Ibex Medical Analytics, a market leader in AI-powered cancer diagnostics, have jointly launched an integrated End-to-End AI-powered Digital Pathology Solution for cancer diagnosis.
A New Standard for Anatomic Pathology Lab Digitization
The new solution is now commercially available in major European markets and sets a new standard for anatomic pathology lab digitization by seamlessly integrating Ibex’s Galen™ platform into Dedalus’ comprehensive Digital Pathology (DP) Solution. It enables full digitization of anatomic pathology labs with a next-generation Anatomic Pathology Information System (AIS) & DP solution, harnessing the power of data and AI for assisted case prioritization, advanced image analysis, and reproducible diagnoses.
Addressing the Growing Demand for Pathology Services
The increasing demand for pathology services posed by the growing number of cancer patients and global shortage of trained pathologists leads pathology laboratories to actively seek efficiency-enhancing solutions that enable labs to maintain high accuracy levels while reducing time to diagnosis and optimizing diagnostic workflows.
Key features of the joint solution include:
– Seamless integration of Ibex’s Galen™ platform into Dedalus’ Digital Pathology (DP) Solution
– AI-powered findings for the diagnosis of prostate, breast and gastric biopsies
– Improved accuracy, AI-powered decision support tools, streamlined reporting, improved laboratory efficiency, and increased diagnostic confidence
“As the premier anatomic pathology information systems provider in Europe, Dedalus takes great pride in partnering with Ibex to introduce this integrated solution. This collaboration harmonizes Dedalus’ expertise in pathology information systems with Ibex’s cutting-edge AI-powered diagnostics. It reflects our commitment to advancing anatomic pathology, equipping pathologists with a state-of-the-art solution that fosters increasingly accurate and timely diagnoses. The potential for enhancing patient outcomes is substantial, and we are leading the way in this transformative journey,” says Marlen Suller, Head of In Vitro Diagnostics Business Unit at Dedalus.
Availability and Demonstration
The joint solution will be presented at the Digital Pathology & AI Congress, taking place in London on December 7-8.